World's Best Scientists 2026 revealed!
Patricia LoRusso

Patricia LoRusso

D-Index & Metrics

Medicine

D-Index
97
Citations
44393
World Ranking
9137
National Ranking
4712

Research.com Recognitions

  • Member of the Association of American Physicians
  • Member of the Association of American Physicians

Overview

Patricia LoRusso is affiliated with Yale University in the United States and has contributed extensively to the fields of medicine and biochemistry, genetics, and molecular biology. Their research is primarily focused on oncology, with particular attention to molecular biology, pulmonary and respiratory medicine, immunology, and radiology, nuclear medicine, and imaging.

The scientist's work covers multiple specialized topics, including:

  • Cancer Immunotherapy and Biomarkers
  • CAR-T cell therapy research
  • PARP inhibition in cancer therapy
  • Monoclonal and Polyclonal Antibodies Research
  • HER2/EGFR in Cancer Research
  • Immunotherapy and Immune Responses
  • Advanced Breast Cancer Therapies

Frequent publication venues for LoRusso include:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • Cancer Research
  • Clinical Cancer Research
  • Regular and Young Investigator Award Abstracts

Notable recent papers authored or co-authored by Patricia LoRusso are:

  • Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019 (2020, CHEST Journal)
  • Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer (2020, Annals of Oncology)
  • A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma (2020, British Journal of Cancer)
  • Pre-clinical animal models are poor predictors of human toxicities in phase 1 oncology clinical trials (2020, British Journal of Cancer)
  • Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial (2023, Nature Medicine)

Their frequent collaborators include Geoffrey I. Shapiro, S. Percy Ivy, Yu Shyr, Erika Hamilton, and Joseph P. Eder. These co-authorships indicate an extensive network of research partnerships, with the highest collaboration count being 18 papers with Geoffrey I. Shapiro.

Patricia LoRusso's primary fields of study consist of medicine and biochemistry, genetics, and molecular biology, with a total of 373 publications in medicine and 141 in molecular biology-related fields. Subfields related to cancer research dominate their portfolio, reflective of the focus on oncology and associated biological and medical specialties.

The scientist has also been recognized as a member of the Association of American Physicians, an acknowledgment of professional standing within the medical research community.

Best Publications

  • Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.

    Nicole M. Kuderer;Toni K. Choueiri;Dimpy P. Shah;Yu Shyr

  • Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.

    D. Ross Camidge;Yung Jue Bang;Eunice L. Kwak;A. John Iafrate

  • Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma

    Daniel D. Von Hoff;Patricia M. LoRusso;Charles M. Rudin;Josina C. Reddy

  • Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile

    Jeffrey Hrkach;Daniel Von Hoff;Mir Mukkaram Ali;Elizaveta Andrianova

  • Treatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449

    Charles M. Rudin;Christine L. Hann;John Laterra;Robert L. Yauch

  • Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer.

    Joseph McLaughlin;Gang Han;Kurt A. Schalper;Daniel Carvajal-Hausdorf

  • First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement

    Josep Tabernero;Geoffrey I. Shapiro;Patricia M. LoRusso;Andres Cervantes

  • Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial

    Ian E Krop;Sung-Bae Kim;Antonio González-Martín;Patricia M LoRusso

  • Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial.

    Roy S. Herbst;Anne-Marie Maddox;Mace L. Rothenberg;Eric J. Small

  • Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer

    Joseph Paul Eder;George F. Vande Woude;Scott A. Boerner;Patricia M. LoRusso

  • Pharmacodynamic Studies of the Epidermal Growth Factor Receptor Inhibitor ZD1839 in Skin From Cancer Patients: Histopathologic and Molecular Consequences of Receptor Inhibition

    Joan Albanell;Federico Rojo;Steve Averbuch;Andrea Feyereislova

  • Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors.

    Patricia M. LoRusso;Charles M. Rudin;Josina C. Reddy;Raoul Tibes

  • Trastuzumab Emtansine: A Unique Antibody-Drug Conjugate in Development for Human Epidermal Growth Factor Receptor 2-Positive Cancer

    Patricia M. LoRusso;Denise Weiss;Ellie Guardino;Sandhya Girish

  • Phase I and Pharmacodynamic Study of the Oral MEK Inhibitor CI-1040 in Patients With Advanced Malignancies

    Patricia M. LoRusso;Alex A. Adjei;Mary Varterasian;Shirish Gadgeel

  • Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial

    Ian E Krop;Sung-Bae Kim;Antonio Gonzalez Martin;Patricia M LoRusso

  • Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases.

    Tianling Chen;James Berenson;Robert Vescio;Regina Swift

  • A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine

    Ian E. Krop;Patricia LoRusso;Kathy D. Miller;Shanu Modi

  • Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors

    Patricia Mucci LoRusso

  • 64Cu-MM-302 positron emission tomography quantifies variability of enhanced permeability and retention of nanoparticles in relation to treatment response in patients with metastatic breast cancer

    Helen Lee;Anthony F. Shields;Barry A. Siegel;Kathy D. Miller

  • Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells.

    Robert H. Vonderheide;Patricia M. LoRusso;Magi Khalil;Elaina M. Gartner

Frequent Co-Authors

Geoffrey I. Shapiro
Geoffrey I. Shapiro Harvard University
Howard A. Burris
Howard A. Burris Sarah Cannon Research Institute
Anthony W. Tolcher
Anthony W. Tolcher Texas Oncology
Ian E. Krop
Ian E. Krop Harvard University
Razelle Kurzrock
Razelle Kurzrock Medical College of Wisconsin
David S. Hong
David S. Hong The University of Texas MD Anderson Cancer Center
Jeffrey R. Infante
Jeffrey R. Infante Janssen (Belgium)
Johanna C. Bendell
Johanna C. Bendell Sarah Cannon Research Institute
Amita Patnaik
Amita Patnaik University of Chicago
Daniel D. Von Hoff
Daniel D. Von Hoff Translational Genomics Research Institute

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in pursuing healthcare careers beyond traditional medical school, there are many flexible online degree options. For those aiming for leadership roles in nursing, considering the easiest online dnp programs can provide a streamlined path to becoming a Doctor of Nursing Practice.

If you are looking to launch your healthcare journey more quickly, an accelerated lpn program allows you to become a Licensed Practical Nurse in less time. Mental health professionals can expand their scope of practice and impact by exploring online msn pmhnp programs that train psychiatric-mental health nurse practitioners.

For those interested in the business and administration side of healthcare, online healthcare administration programs offer a flexible route to leadership positions in hospitals, clinics, and healthcare organizations.

Whether your goal is clinical practice or healthcare management, online degrees create new pathways to meaningful and high-demand career options across the industry.

Best Scientists Citing Patricia LoRusso

Trending Scientists

Recently Published Articles